Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2006; 12(40): 6515-6521
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6515
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6515
Figure 1 Immunohistochemically detectable nodal microinvolvement with monoclonal antibody Ber EP4 (×400).
Figure 2 Immunohistochemically detectable bone marrow microinvolvement with monoclonal antibody AE1/AE3 (×400).
Figure 3 Overall survival according to the presence or absence of nodal microinvolvement in immunohistochemistry for patients alive at least 13 wk after surgery.
Median: Not yet reached-NYR vs 13 mo; Mean: 81 (SD 15, 95% CI 52-109) vs 16 (SD 2, 95% CI 12-20); 2-yr overall survival 66% vs 20%; 5-yr overall survival 50% vs 0%.
Figure 4 Overall survival according to the presence or absence of nodal metastases in conventional histopathology and immunohistochemistry for patients alive at least 13 wk after surgery.
Median: Not yet reached-NYR vs 13 mo vs 10 mo; Mean: 90 (SD 15, 95% CI 60-119) vs 17 (SD 3, 95% CI 11-23) vs 14 (SD 2, 95% CI 7-13); 2-yr overall survival 66% vs 20%; 5-yr overall survival 50% vs 0%.
- Citation: Yekebas EF, Bogoevski D, Bubenheim M, Link BC, Kaifi JT, Wachowiak R, Mann O, Kutup A, Cataldegirmen G, Wolfram L, Erbersdobler A, Klein C, Pantel K, Izbicki JR. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. World J Gastroenterol 2006; 12(40): 6515-6521
- URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6515.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6515